Physician profile
Daniel Ahoubim
NPI 1740415686
$6,347.90
in general payments reported to CMS, 2019-2025
31 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $129 · 2021: $683 · 2022: $1,055 · 2023: $1,347 · 2024: $1,679 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,141 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.57 |
| Education | $189.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $689.59 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Sk Life Science, INC. | $644.81 | 2021-2025 | |
| Harmony Biosciences LLC | $626.04 | 2021-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $591.94 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $533.68 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $365.25 | 2021-2025 | Ultomiris, Soliris |
| Kyowa Kirin, INC. | $323.22 | 2022-2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $257.10 | 2020-2025 | |
| Lilly USA, LLC | $250.51 | 2021-2025 | Emgality, Kisunla, Reyvow |
| Neurelis, INC. | $206.39 | 2024-2025 | Valtoco |
| Argenx US, INC. | $196.37 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $164.18 | 2023-2025 | Xywav |
| Otsuka America Pharmaceutical, INC. | $161.30 | 2023-2025 | Rexulti |
| Lundbeck LLC | $156.66 | 2024-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $118.50 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $107.70 | 2022-2025 | |
| Celgene Corporation | $106.55 | 2024-2025 | Zeposia |
| Livanova USA, INC. | $102.28 | 2022-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $92.20 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $89.97 | 2022-2023 | Onpattro |
| Banner Life Sciences, LLC | $87.61 | 2022-2024 | |
| Genentech USA, INC. | $83.89 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $80.98 | 2024-2025 | Briviact |
| Tanabe Pharma America, INC. | $67.00 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.75 | 2022 | |
| Ge Healthcare | $50.10 | 2022-2025 | |
| Horizon Therapeutics Plc | $34.44 | 2023 | Uplizna |
| Axsome Therapeutics, INC. | $31.98 | 2025 | Symbravo |
| Impel Pharmaceuticals INC. | $29.03 | 2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $21.47 | 2025 | Qelbree |
| Astrazeneca Pharmaceuticals Lp | $18.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ahoubim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.